English transcript

Yeah, so to be clear, this was a purely observational study and has lots of limitations as a result

of the nature of the way it was done.

What we did is we looked at nearly 200 patients, so it was 197 of them, with many, many different

brands of cancer and looked at how taking the combination of ivermectin and mebendazole,

what impact that had, if any, on their cancer.

And lo and behold, what we found really was quite compelling.

Eighty-four percent of people had a positive outcome, meaning that 48% had either no evidence

of cancer at all at the end or significant remission of their cancer.

Another 36% had no progression of their disease, and only 15% total of these people had progression

of their cancer.

Now, again, lots of limitations in a study like this.

Some people are also getting radiation.

Some people may or may not have been doing chemotherapy.

We have all of that data.

So there were a mixture of things.

But the fact that 84% of the people taking ivermectin and mebendazole had a positive

outcome, at a minimum, Drew, should motivate further study, should motivate big dollars

to be spent on a large, well-randomized control trial to investigate this, because there's

no question we've known for decades ivermectin in particular has very, very powerful anti-cancer

properties, 12 different mechanisms by which it interrupts cancer growth and progression.

It is an incredibly safe drug, great safety profile, relatively inexpensive, and in comparison

to chemotherapy, wildly inexpensive.

And most importantly, it actually supports your immune system rather than destroying

it, which is what typical chemotherapy, traditional chemotherapy may kill cancer cells, but it

also kills a heck of a lot of good stuff in the process.